Shibuya-ku, Tokyo, Japan, Japan, Jun 24, 2022, 06:24 /Comserve / -- The report predicts the global Benign Prostatic Hyperplasia Treatment Market to grow at a healthy CAGR over the forecast period from 2022-2031.
The global benign prostatic hyperplasia treatment market is projected to reach USD 14.1 billion by 2031 from USD 10.8 billion in 2021, at a CAGR of 5.3% from 2022 to 2031.
The growth of this market is driven owing to the increasing prevalence of benign prostatic hyperplasia, the rising preference for minimally invasive surgeries, increasing obesity rate, and investments, funds, and grants for research in the field of BPH treatment. Also, the emerging markets and promising product pipeline is anticipated to offer an opportunity for the growth of the market during the forecast period.
“Drug treatment is expected to hold the largest share of the benign prostatic hyperplasia treatment market, by type in 2021.”
Based on the type, the BPH treatment market is segmented into drug treatment and surgical treatment. Drug treatment is the largest and the fastest-growing segment in this market. This can primarily be attributed to the use of medications as the first line of treatment among men with mild to moderate symptoms of BPH.
“Home healthcare is expected to hold the largest share of the benign prostatic hyperplasia treatment market, in 2021.”
Based on the end user, the market is segmented into home healthcare and hospitals & clinics. In 2019, home healthcare accounted for the largest share of this market, as most patients are prescribed medications over surgery. Patients are also advised to continue taking medications for a few weeks post-surgery and may even require catheters for a few days. As a result, the emphasis in his market is skewed toward home healthcare over hospital care.
“North America commanded the largest share of the benign prostatic hyperplasia treatment market in 2021.”
On the basis of region, the benign prostatic hyperplasia treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2019, North America commanded the largest share of the benign prostatic hyperplasia treatment market. The large share of this market segment can be attributed to the rising geriatric and obese population and the availability of research funding are the major factors driving the market growth. Initiatives by key players are also expected to contribute to the market.
Click Here To Get The Sample PDF Report: https://www.sdki.us/sample-request-114070
Breakdown of supply-side primary interviews, by company type, designation, and region:
The some of the major players operating in this market are GlaxoSmithKline plc. (UK), Astellas Pharma Inc. (Japan), Merck & Co., Inc. (US), Eli Lilly and Company (US), and Teleflex Incorporated (US).
List of Companies Profiled in the Report
Research Coverage
This report studies the benign prostatic hyperplasia treatment market based on type, end user and region. The report also analyzes factors (such as drivers, restraints, challenges, and opportunities) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total benign prostatic hyperplasia treatment market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
Click Here To Get The Sample PDF Report: https://www.sdki.us/sample-request-114070
Frequently asked questions
• What are the growth opportunities in the benign prostatic hyperplasia treatment market across major regions in the future?
• Which type of drug is expected to hold the largest share in the benign prostatic hyperplasia treatment market?
• Which form of surgery has been widely used in BPH treatment?
• Which region has a well-developed benign prostatic hyperplasia treatment market?
• What is the impact of COVID-19 on benign prostatic hyperplasia treatment market?
The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.
For more information, please contact:
Lauren BrownShibuya Data Count
Email: sales@sdki.jp
Tel: + 81 50 50509159
Related Links
https://www.sdki.us/